Skip to main content
Premium Trial:

Request an Annual Quote

Galapagos Genomics Identifies Several Drug Targets

NEW YORK, June 7 (GenomeWeb News) - Galapagos Genomics said today that it has identified, validated, and filed patent applications for several novel drug targets in Alzheimer's disease, osteoporosis, osteoarthritis, rheumatoid arthritis, and asthma.

 

Galapagos identified the targets using its FlexSelect adenoviral-based over-expression and SilenceSelect siRNA gene knockdown technologies.

 

"We are very pleased to see that our target discovery engine in combination with our disease biology expertise has delivered an exiting set of proprietary targets that are ready to be taken into small molecule screening," Onno van de Stolpe, CEO of Galapagos, said in a statement.

 

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.